# Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

> **NCT04665765** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 41 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma Unclassifiable
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
- Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
- Refractory Transformed B-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Ifosfamide
- **DRUG:** Polatuzumab Vedotin
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT04665765
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-18
- **Primary completion:** 2022-07-26
- **Final completion:** 2026-07-01
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665765, "Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04665765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*